158 related articles for article (PubMed ID: 32207198)
1. Microscopic and functional changes observed with dynamic optical coherence tomography for severe refractory atopic dermatitis treated with dupilumab.
Manfredini M; Liberati S; Ciardo S; Bonzano L; Guanti M; Chester J; Kaleci S; Pellacani G
Skin Res Technol; 2020 Nov; 26(6):779-787. PubMed ID: 32207198
[TBL] [Abstract][Full Text] [Related]
2. Improve the dupilumab therapy evaluation with dermoscopy and high-frequency ultrasound in moderate-to-severe atopic dermatitis.
Liu Z; Niu Z; Zhang D; Liu J; Zhu Q
Skin Res Technol; 2023 Jan; 29(1):e13260. PubMed ID: 36704877
[TBL] [Abstract][Full Text] [Related]
3. Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic.
Tánczosová M; Kojanová M; Arenbergerová M; Arenberger P; Doležal T; Štrosová D; Fialová J; Gkalpakiotis S
Cent Eur J Public Health; 2022 Mar; 30(1):46-50. PubMed ID: 35421298
[TBL] [Abstract][Full Text] [Related]
4. Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic dermatitis: An observational study.
Cristaudo A; Pigliacelli F; Sperati F; Orsini D; Cameli N; Morrone A; Mariano M
Skin Res Technol; 2021 Sep; 27(5):810-813. PubMed ID: 33651467
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study.
Torres T; Paiva-Lopes MJ; Gonçalo M; Claro C; Oliveira M; Gomes J; Vieira AP; Amoedo P; Alpalhão M; Nogueira M; Santiago F; Henrique M; Amaro C; Esteves T; Alves J; Cerejeira D; Mendes-Bastos P; Pestana M; Ramos L; Rocha J; Carvalho R; Teixeira L; Selores M; Mota A; Filipe P;
J Dermatolog Treat; 2022 Aug; 33(5):2554-2559. PubMed ID: 35083945
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin.
Leung DYM; Bissonnette R; Kreimer S; Berdyshev E; Bafna S; Lyubchenko T; Richers BN; Garcia S; Ramirez-Gama M; Hall CF; Xiao O; Taylor P; Boguniewicz M; Levit NA; Agueusop I; Zhang A; Goleva E
J Allergy Clin Immunol Pract; 2023 May; 11(5):1421-1428. PubMed ID: 36958520
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
[TBL] [Abstract][Full Text] [Related]
8. A Short Cycle of Narrow-Band UVB Phototherapy in the Early Phase of Dupilumab Therapy Can Provide a Quicker Improvement of Severe Atopic Dermatitis.
Rossi M; Rovati C; Arisi M; Tomasi C; Calzavara-Pinton I; Venturini M; Calzavara-Pinton P
Dermatology; 2021; 237(3):407-415. PubMed ID: 33401279
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis.
Hartmann J; Moitinho-Silva L; Sander N; Harder I; Häsler R; Rodriguez E; Haufe E; Kleinheinz A; Abraham S; Heratizadeh A; Weisshaar E; Schäkel K; Handrick C; Augustin M; Wollenberg A; Staubach-Renz P; Ertner K; Sticherling M; Schwarz B; Quist S; Wiemers F; Schenck F; Wildberger J; Tittmann L; Lieb W; Schmitt J; Werfel T; Weidinger S;
Allergy; 2023 Aug; 78(8):2290-2300. PubMed ID: 37032440
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic Profiling of Tape-Strips From Moderate to Severe Atopic Dermatitis Patients Treated With Dupilumab.
Mikhaylov D; Del Duca E; Olesen CM; He H; Wu J; Ungar B; Estrada Y; Zhang N; Chowdhury M; Clausen ML; Krueger JG; Pavel AB; Agner T; Guttman-Yassky E
Dermatitis; 2021 Oct; 32(1S):S71-S80. PubMed ID: 34405829
[TBL] [Abstract][Full Text] [Related]
12. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
13. Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers.
He H; Olesen CM; Pavel AB; Clausen ML; Wu J; Estrada Y; Zhang N; Agner T; Guttman-Yassky E
Front Immunol; 2020; 11():1768. PubMed ID: 32849633
[TBL] [Abstract][Full Text] [Related]
14. Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study.
Strober B; Mallya UG; Yang M; Ganguli S; Gadkari A; Wang J; Sierka D; Delevry D; Kimball AB
JAMA Dermatol; 2022 Feb; 158(2):142-150. PubMed ID: 34910086
[TBL] [Abstract][Full Text] [Related]
15. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
17. Ultra-High Frequency UltraSound (UHFUS) Assessment of Barrier Function in Moderate-to-Severe Atopic Dermatitis during Dupilumab Treatment.
Dini V; Iannone M; Michelucci A; Manzo Margiotta F; Granieri G; Salvia G; Oranges T; Janowska A; Morganti R; Romanelli M
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685259
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
[TBL] [Abstract][Full Text] [Related]
19. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.
Lor M; Villa N; Holland V
Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092
[TBL] [Abstract][Full Text] [Related]
20. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
